FindMyKOL
Clinical trialNCT02059850WithdrawnPhase 1Interventional

NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

NCT02059850 is a phase 1 interventional trial sponsored by Fred Hutchinson Cancer Center. As of 21 Nov 2026, it was withdrawn. It studies Autologous NY-ESO-1-specific CD8-positive T Lymphocytes and Cyclophosphamide in Adult Synovial Sarcoma, Myxoid/Round Cell Liposarcoma and 3 more conditions. The registry lists an enrollment of 0 participants at 1 site in 1 country. The registry lists a start date of 31 Jul 2014 and a primary completion date of 31 Jan 2016. One of its registered investigators has a FindMyKOL profile.

SponsorFred Hutchinson Cancer Center →Enrollment0Adult Synovial SarcomaMyxoid/Round Cell LiposarcomaRecurrent Adult Soft Tissue SarcomaStage III Adult Soft Tissue SarcomaStage IV Adult Soft Tissue Sarcoma
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT02059850
FieldValue
Registry IDNCT02059850
StatusWithdrawn
PhasePhase 1
Study typeInterventional trial
Lead sponsorFred Hutchinson Cancer Center
Enrollment0
Registered sites1
Countries1
ConditionsAdult Synovial Sarcoma, Myxoid/Round Cell Liposarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma and Stage IV Adult Soft Tissue Sarcoma
DrugsAutologous NY-ESO-1-specific CD8-positive T Lymphocytes and Cyclophosphamide
Start31 Jul 2014
Primary completion31 Jan 2016
Study completion31 Jan 2016
Last update posted3 Feb 2016

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I trial studies the side effects and best way to give NY-ESO-1 specific T cells after cyclophosphamide in treating patients with advanced synovial sarcoma or myxoid/round cell liposarcoma. Placing a gene that has been created in the laboratory into white blood cells may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving NY-ESO-1 specific T cells with cyclophosphamide may kill more tumor cells.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Washington, United States1 site
  • Fred Hutchinson Cancer Research Center/university of Washington Cancer Consortium

    Seattle

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashington: 1 siteWA1MontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Autologous NY-ESO-1-specific CD8-positive T LymphocytesCyclophosphamide →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT02059850

Each answer restates registry values shown on this page.

What is NCT02059850?

NCT02059850 is a phase 1 interventional trial sponsored by Fred Hutchinson Cancer Center. It studies Autologous NY-ESO-1-specific CD8-positive T Lymphocytes and Cyclophosphamide in Adult Synovial Sarcoma, Myxoid/Round Cell Liposarcoma and 3 more conditions.

Who leads NCT02059850?

The registry names Seth Pollack (principal investigator, Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium) as the overall official.

Where does NCT02059850 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT02059850 study?

The registered drug and biological interventions are Autologous NY-ESO-1-specific CD8-positive T Lymphocytes and Cyclophosphamide.

When did NCT02059850 end?

The registry lists a primary completion date of 31 Jan 2016 and a study completion date of 31 Jan 2016. The sponsor last updated the record on 3 Feb 2016.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.